Lee Greenberger Discusses Blood Cancer Research and the Leukemia and Lymphoma Society

Article

Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses how the society contributes to blood cancer research.

Lee Greenberger, PhD, chief scientific officer, The Leukemia & Lymphoma Society, discusses how the society contributes to blood cancer research.

The Leukemia & Lymphoma Society recently passed the $1 billion mark in research investment, Greenberger said. The society currently has 320 active programs available.

The journey from a laboratory discovery to a therapy that can control disease takes about 10 years. Sustained funding is needed in order to make progress in this field, Greenberger says, and the society’s volunteers, advocates, and cancer patients step up in order to make progress in the field happen.

To learn more about The Leukemia & Lymphoma Society, visit www.lls.org.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Image of a man in scrubs with short hair and glasses
Redeployment Engages Oncology PA Skills, Reduces Burnout
Photo of a woman with brown hair and bangs, surrounded by a blue border
Evaluating Options for Second-Line HR+, HER2- Breast Cancer Treatment
Optimizing RCC Treatment: Integrating Patient-Reported Outcomes and Clinician Insights
Optimizing RCC Treatment: Integrating Patient-Reported Outcomes and Clinician Insights
Quality of Life and Treatment Experience: Patient-Reported Outcomes from TiNivo-2
Quality of Life and Treatment Experience: Patient-Reported Outcomes from TiNivo-2
TiNivo-2 Phase 3 Trial: Survival Data and Practical Approaches to Dose Management in Practice
TiNivo-2 Phase 3 Trial: Survival Data and Practical Approaches to Dose Management in Practice
Optimizing VEGFR-TKI Therapy: Perspectives on Patient Selection and Management Strategies in Clinic
Optimizing VEGFR-TKI Therapy: Perspectives on Patient Selection and Management Strategies in Clinic
Tivozanib Monotherapy Efficacy Profile and Clinical Management Strategies in Advanced RCC
Tivozanib Monotherapy Efficacy Profile and Clinical Management Strategies in Advanced RCC
VEGFR-TKI Tivozanib: Rational Treatment Selection Post-ICI Progression
VEGFR-TKI Tivozanib: Rational Treatment Selection Post-ICI Progression
Image of a woman with dark hair wearing a floral shirt in front of a blurred background
Nurse Practitioners in Cancer Research: Recruitment, Protocols, and Documentation
Sequencing Strategies in RCC: Optimizing Treatment Selection After IO-Based Therapy
Sequencing Strategies in RCC: Optimizing Treatment Selection After IO-Based Therapy
Related Content
Aerial photo of four medical professionals talking in a huddle; two are wearing scrubs and two are wearing lab coats

Shared Model of Care Post-HCT Offers Safe Follow-Up, Reduces Patient Burden

Bridget Hoyt
Published: March 19th 2025 | Updated: March 19th 2025
Article

Alternating post-HCT care between specialized facilities and local cancer centers produced noninferior non-relapse mortality and similar quality of life to usual care.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Simple white line illustration of a clipboard that says "FDA" at the top, with a checkmark symbol overlapping the clipboard

Oncology Drugs Approved by the FDA in January 2025

Darlene Dobkowski, MA
February 3rd 2025
Article

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Lindsay Fischer
December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

green background with blue text indicating FDA and green text indicating approved with a green checkmark

FDA Approves Treosulfan With Fludarabine for alloHSCT Conditioning in AML and MDS

Bridget Hoyt
January 24th 2025
Article

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic stem cell transplantation.

dark blue background with three people around a clip board

NCCN Recommends ctDNA Testing for MRD Assessment in DLBCL

Ashling Wahner
January 14th 2025
Article

NCCN guidelines now recommend ctDNA testing for MRD assessment for patients with PET-positive DLBCL after treatment.